Proliat prostatet cancer – pro
Prolia ® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia ® also reduced the incidence of vertebral fractures. Clinical trials have shown that the drug is effective when it’s used over a 3-year period.
Hegemann M, Bedke J, Stenzl A, Todenhöfer T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol. 2017;9(3-4): 81-88. Published 2017 Feb 6.
Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-755.
NCCN Prostate Cacner 2021